Wantai BioPharma advances HIV self-testing, rotavirus vaccine

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (Wantai BioPharma) announced the acceptance of its clinical trial application for the recombinant trivalent rotavirus subunit vaccine (Escherichia coli) by the National Medical Products Administration. This vaccine, developed in collaboration with Xiamen University and Xiamen Wantai Canghai Biotechnology Co., Ltd., is designed to prevent rotavirus gastroenteritis and has incurred R&D expenses of approximately CNY 6,585.31 as of November 30, 2025.

In a separate announcement, Wantai BioPharma obtained a medical device registration certificate for its independently developed HIV 1+2 antibody oral mucosal exudate detection reagent kit (colloidal gold method). This product, the first of its kind approved in China for self-testing using oral fluid, expands the company's HIV rapid self-testing product line, which now covers saliva, urine, and blood samples.

The new HIV self-test aligns with national efforts to promote accessible testing as outlined in the "China Plan for the Containment and Prevention of AIDS (2024–2030)." Both developments are crucial steps in strengthening Wantai BioPharma's product portfolio and market competitiveness in the diagnostic and vaccine sectors.